Table 1 (abstract P442). Comparison of primary efficacy endpoint and safety parameters between overall trial population and Indian subset of patients
From: 40th International Symposium on Intensive Care & Emergency Medicine
Parameters | Overall Population (n=258) | Overall Population (n=258) | Indian Subset (n=12) | Indian Subset (n=17) |
|---|---|---|---|---|
All- cause mortality (Day 42) | 48 (19) | 52 (20) | 5 (41.6) | 5 (29.4) |
Adjusted Treatment Difference | -1% | Â | 12.2% | Â |
TEAE leading to treatment discontinuation | 37 (14) | 59 (23) | 2 (16.7) | 4 (23.5) |
Ocular toxicity | 39 (15) | 69 (27) | 0 | 2 (11.8) |
Skin and Subcutaneous Tissue disorder | 86 (33) | 110 (42) | 1 (8.3) | 1 (5.9) |
Hepatobiliary disorder | 23 (9) | 42 (16) | 0 | 1 (5.9) |